Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy

• Published in: Cancer letters Vol. 225; no. 2; pp. 215 - 223
• Main Authors: Cecic, Ivana, Serrano, Katherine, Gyongyossy-Issa, Maria, Korbelik, Mladen
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 28.07.2005; Elsevier Limited
• Subjects: Animals; Blood; Cancer; Cancer therapies; Carcinoma, Lewis Lung - drug therapy; Carcinoma, Lewis Lung - immunology; Colleges & universities; Complement Activation - immunology; Complement C3 - analysis; Complement C3 - immunology; Complement C3 - metabolism; Complement Pathway, Alternative; Complement system; Homeostasis; Immune system; Light; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Medical research; Mice; Mice, Inbred C57BL; Mouse LLC tumor model; Photochemotherapy; Photodynamic therapy; Proteins; Receptors, Complement - antagonists & inhibitors; Receptors, Complement - immunology; Receptors, Complement - metabolism; Rodents; Signal transduction; Time Factors; Tumors; C3; Complement system; Photodynamic therapy; Mouse LLC tumor model
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2004.11.059

Following treatment of Lewis lung carcinomas (LLC) by Photofrin-mediated photodynamic therapy (PDT), tumor tissues and sera of host mice were collected for the analysis of complement activity. Elevated tumor C3 levels were detected between 1 and 24 h after PDT, while serum C3 levels increased significantly at 24 h post therapy. Increased alternative complement pathway activity in the serum was evident between 1 and 3 days post PDT. Blocking C3a- or C5a-receptors in the host mice decreased the efficacy of PDT in producing LLC tumor cures, supporting the importance of complement action in PDT-mediated tumor destruction.